ArticleFrontiers in oncology2026
Pathologic response after total neoadjuvant therapy in stage II-III rectal cancer: preliminary results from a prospective study from Vietnam.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Total neoadjuvant therapy (TNT) is increasingly recommended for locally advanced rectal cancer (LARC), yet data from developing countries remain limited. In Vietnam, constraints in diagnostic access, radiotherapy availability, and multidisciplinary coordination may affect treatment feasibility and outcomes. Objective: To evaluate pathological response, safety, and perioperative outcomes of TNT for stage II-III rectal cancer in a Vietnamese oncology center. Methods: This prospective single-arm study enrolled 101 patients who received long-course chemoradiotherapy followed by consolidation capecitabine-oxaliplatin (CAPOX) or 5-fluorouracil/leucovorin-oxaliplatin (FOLFOX)before total mesorectal excision. Pathologic response and tumor regression grade were assessed. Results: Among 95 resected patients, pathological complete response (pCR) was 35.7%, and good regression (TRG 0-1) was achieved in 70.4%. Treatment completion was high (94.1%), with acceptable toxicity and no treatment-related mortality. Conclusion: TNT is feasible, safe, and achieves response outcomes comparable to global benchmarks, supporting its integration into rectal cancer management in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.